Bacterial Infections

Kevin Alby and Melissa B. Miller

Abstract
Molecular techniques have revolutionized the detection and identification of microorganisms. Real-time PCR has allowed for the rapid and accurate detection of MRSA, VRE, and group B Streptococcus. The identification of difficult and slow-growing organisms has been expedited by sequence-based methods such as 16S rRNA gene sequencing. Rapid identification of organisms and detection of resistance markers directly from positive blood culture bottles has become a reality. Finally, a transformation is taking place with the introduction of MALDI-TOF into clinical laboratories that promises to improve the accuracy and speed of bacterial and fungal identifications by days. The advantages of these methodologies and their associated clinical applications, along with their inherent pitfalls and problems, are elucidated in this chapter.

Keywords
MRSA • Staphylococcus aureus • VRE • Enterococcus • Group B Streptococcus • Antimicrobial resistance • Mass spectrometry • MALDI-TOF • 16S rRNA • Tuberculosis • Sepsis • Molecular epidemiology

Introduction
As the general population ages, the incidence of chronic conditions rises, the prevalence of antimicrobial resistance increases, and emerging pathogens arise, the laboratory diagnosis of infectious diseases has evolved and become more complex. As the complexity of diagnostic microbiology has increased, so have the methods employed to detect infectious agents. The implementation of molecular technology in the clinical microbiology laboratory in some cases has augmented traditional methods, such as culture and serology, while in other circumstances it has completely replaced traditional methods. For routine bacteriology (i.e., blood cultures, urine cultures, and respiratory cultures), culture has remained the gold standard primarily based on a lower cost and the potential complex nature of infections. However, in situations where low quantities of the pathogen may be present, the patient may have received antibiotics prior to specimen collection, the etiologic agent may require unusual culture conditions, or a more rapid turnaround time is needed, molecular testing approaches are particularly beneficial.

Currently, the optimal use of molecular techniques in microbiology resides with specimens in which a limited number of pathogenic organisms are sought (i.e., detection of methicillin-resistant Staphylococcus aureus from nares or vancomycin-resistant Enterococcus from rectal swabs) and in cases where the enhanced sensitivity, decreased turnaround time, and/or patient impact of molecular methods outweighs the increased cost to the laboratory.
(i.e., molecular identification of organisms directly from positive blood cultures). A particularly exciting transition in clinical microbiology is the use of mass spectrometry (MS) for the identification of a wide spectrum of bacterial and fungal organisms as well as the detection of antimicrobial resistance. This chapter discusses the most common molecular methods and their applications in clinical bacteriology laboratories, including the associated advantages and disadvantages.

**Bacterial Identification**

**Probe Hybridization**

The molecular methods used for the identification of bacterial organisms cultured from patient specimens include direct probe hybridization and sequencing. Direct probe hybridization can be used for culture confirmation as well as direct detection of organisms from clinical material. Both nucleic acid probes and peptide nucleic acid (PNA) probes are commercially available.

Probes are single-stranded oligonucleotides that vary in size from 20 base pairs (bp) to a few kilobases, but are generally less than 50 bp. Probe specificity is defined by the nucleic acid sequence of the probe. Bacterial identification using probes to 16S rRNA or 23S rRNA are commonly used due to the relatively high copy number of rRNAs in bacteria which increases the sensitivity of direct detection. Further, rRNA sequences contain conserved regions in addition to hypervariable regions allowing for the level of identification to be varied depending on the probe sequence. Commercially available probes for culture confirmation include Group B Streptococcus, Listeria monocytogenes, Neisseria gonorrhoeae, Staphylococcus aureus, Streptococcus pneumoniae, and several mycobacteria including *M. tuberculosis* (Hologic, San Diego, CA). In addition, probes for direct detection of group A *Streptococcus* from throat swabs are available (Hologic). Although more expensive than conventional culture and identification methods, probe-based detection and identification methods have moderately increased sensitivity and specificity and decreased turnaround time [1]. However, both false-negative and false-positive results may occur. Bacterial strains may possess polymorphisms that prevent probe hybridization [2, 3] or different strains may contain similar sequences that result in cross-reactivity [4, 5]. Additional disadvantages of probe hybridization methods are the limited number of commercial probes and the inability to probe clinical specimens directly.

In situ hybridization (ISH) allows for the detection of nucleic acid sequences in cells or tissues fixed to glass slides. Probes, which can be DNA, RNA, or PNA, are typically short (15–30 bps) allowing for easier penetration and access to the target sequence. Both colorimetric and fluorescent ISH (FISH) probes are used in histopathology and clinical microbiology. Advantages of ISH in histopathology are the ability to evaluate the host tissue response and identification of the specific cells containing the infectious agent(s). In addition, “non-culturable” or difficult to culture organisms can be detected by ISH, i.e., *Tropheryma whipplei* for Whipple’s disease. Disadvantages include autofluorescence by some microorganisms (including *Pseudomonas, Legionella*, many yeasts, and molds), specificity and reliability of certain probe sequences, insufficient probe penetration of sample material, secondary structure of target sequence, low target content, and photobleaching [6].

In clinical microbiology, the direct identification of microbial organisms in patient samples or cultures often is determined using commercial PNA-FISH probes (AdvanDx, Woburn, MA). PNA probes have a neutral peptide-like backbone, as opposed to the negatively charged sugar-phosphate backbone of DNA probes [7]. However, like DNA probes, PNA probes hybridize to DNA and RNA in a sequence-specific manner and can be fluorescently labeled for ease of detection. Reported advantages of PNA probes include stronger and faster hybridization, discrimination of one bp difference, resistance to nucleases and proteases, survival under stringent conditions (e.g., high temperature) that allow for access to regions with secondary structure, and increased hydrophobicity that allows for penetration of cell membranes during ISH [7]. Commercial PNA probes include many multi-labeled probe kits for the discrimination of morphologically similar organisms including *Staphylococcus aureus* / coagulase-negative *Staphylococcus*, *Enterococcus faecalis* / other enterococci, *Escherichia coli* / *Pseudomonas aeruginosa*, gram-negative rods (*E. coli*, *P. aeruginosa*, *Klebsiella pneumoniae*), yeast (*C. albicans* / *parapsilosis*, *C. tropicalis*, and *C. glabrata* / *krusei*), and Group B *Streptococcus* (AdvanDx, Inc., Woburn, MA). PNA-FISH probes are used by clinical laboratories for the identification of organisms from positive blood culture bottles in less than 2.5 h, which has a significant positive impact on patient care and institutional cost savings [8–11].

**Sequencing**

In many larger laboratories, sequencing is used to rapidly and accurately identify organisms. Sequencing is more rapid than conventional methods, but initial growth of an isolate is still required prior to sequencing. Ideal applications of sequencing for organism identification include *Mycobacterium* spp., aerobic actinomycetes including *Nocardiopsis* spp., select anaerobes and gram-positive bacteria, which are organisms that are typically slow-growing or dif-
difficult to identify by routine methods. Sequencing can also be used to identify organisms that cannot be cultured because they are inherently difficult to grow or as a result of antibiotic therapy. In this situation, sequencing would need to be performed directly from the clinical specimen, but this practice must be used with caution and only for specimens from sterile sites. A substantial body of evidence exists for direct sequencing from explanted heart valves for the identification of organisms causing endocarditis [12, 13].

Many bacterial genome regions are used for sequence-based identification in clinical laboratories, but the 16S rRNA gene is the most common target. The 16S rRNA gene encodes for the highly conserved rRNA associated with the small subunit of the ribosome and is often used for taxonomic purposes and species identification. While 16S rRNA is highly conserved among bacteria, nucleotide variations unique to each species are concentrated in specific regions. The entire gene is 1,550 bp including the conserved and variable regions, but discriminatory sequence can generally be obtained using 500 bp [14]. Universal primers complementary to the conserved regions on either side of the variable region permit amplification from all bacterial species and the resulting amplicon contains unique sequence for identification. Commercial research use only kits are available for sequencing of 16S rRNA (MicroSeq; Applied Biosystems) (Thermo Fisher Scientific, Waltham, MA), but many clinical laboratories use laboratory-developed protocols. Notably, some organisms are identical by 16S rDNA sequencing (e.g., M. chelonae and M. abscessus, S. pneumoniae and S. mitis). However, some of the identical organisms by 16S rDNA sequencing can be differentiated by sequencing other genes, such as those of the internal transcribed space (ITS) region, rpoB, secA, or hsp65 [15–17]. Sequence results are more robust than conventional culture methods because they are less subjective if a comprehensive and accurate database is used for sequence comparison. Analysis of the sequence data involves evaluating the quality of the sequence obtained and subsequent comparison of the sequence with known sequences through public and/or commercial databases, such as NCBI GenBank, MicroSeq, Integrated Database Network System (SmartGene, Raleigh, NC), or RipSeq (Isentio, Palo Alto, CA). Once an isolate is growing in culture, the entire procedure can be done in about 1.5 work days. Beyond the relatively long time to result compared to mass spectrometry, other limitations are the quality of public databases or the expense of access to curated databases, and the similarity of 16S rRNA sequences of some organisms.

**Mass Spectrometry**

A major advancement in bacterial identification is the routine use of mass spectrometry (MS) in clinical microbiology laboratories [18]. Traditionally, bacterial identification is achieved by performing a number of biochemical reactions to identify the unique combination of phenotypic properties that are specific to a particular microorganism. Originally performed individually, these phenotypic tests have been streamlined and are now performed on automated instruments. Although automated systems have reduced the time to identification relative to traditional methods, there is still room for improvement.

The use of MS to identify organisms was first described in the mid-1970s [19], but not until the advent of using matrix assisted MS was the reliability and reproducibility sufficient for clinical applications [20]. The type of MS most commonly used in clinical microbiology is Matrix Assisted Laser Desorption/Ionization Time Of Flight (MALDI-TOF) MS. As illustrated in Fig. 49.1, the core of MALDI-TOF MS for bacterial identification is that differences in DNA lead to

![Figure 49.1](image-url)  
**Figure 49.1** Schematic of MALDI-TOF mass spectrometry for differentiation of two organisms (A and B). Differences in DNA (1) encode for different protein products (2) which are differentially fragmented under laser excitation (3). These fragmented proteins produce organism-specific spectra (4), which are compared against a reference database of spectra (5) for organism identification.
differences in the protein composition of an organism, and the differences in protein composition can be resolved by MALDI-TOF MS. The technology works by using the laser to create a cloud of ions to which a current is applied and released into a flight chamber. The ions are generated from the bacterial isolate that has been smeared onto a target slide and overlaid with a matrix solution (typically α-cyano-4-hydroxycinnamic acid). The matrix solution is critical for even distribution of the laser energy, generation of primarily singly charged ions, and reproducible results. The process of using smeared bacterial isolates is often referred to as whole cell or intact cell MS (WCMS or ICMS) [21, 22]. As the ions travel through the flight chamber they are separated according to their size and charge, with the smallest and most highly charged particles moving fastest through the chamber. The ions strike a detector at the end of the chamber, and a spectrum is generated that provides the relative quantity of ions of a particular mass–charge ratio. These spectra are algorithmically compared to a reference database with identity and confidence values assigned.

Much like 16S rRNA gene sequencing, the strength of this application relies on a robust reference database for comparison [18]. Several studies have shown that identification rates significantly increase after database augmentation [23–25]. Also, much as quality sequence reads are necessary for identification, high quality spectra are a must for good reference matching and identification. Ideal spectra for identification typically consist of proteins in the 2–20 kDa range, which is rich in ribosomal and other cytoplasmic proteins. Obtaining quality spectra using WCMS can be difficult with organisms such as mycobacteria, filamentous fungi, and yeasts, due to their rigid cell walls [18, 26]. Therefore, these organisms must undergo an additional extraction step to make the internal cellular proteins more accessible for ionization. The most basic extraction step is to apply a formic acid solution to the smeared spot and allow it to dry before adding the matrix solution. Higher order bacteria, such as mycobacteria and Nocardiia spp., and filamentous fungi require a more rigorous extraction, typically involving bead beating, formic acid, and acetonitrile treatments [27]. In general, MALDI-TOF MS performs well, typically identifying >90 % of routine organisms to the correct species [18, 28, 29]. Two MALDI-TOF MS platforms currently are used in clinical microbiology laboratories: the MALDI Biotyper (Bruker Daltronics, Billerica, MA) and VITEK MS (bioMerieux, Durham, NC) each offering FDA-cleared databases. Additional developments in MALDI-TOF MS for the clinical microbiology laboratory include detection of antimicrobial resistance and direct pathogen detection from blood cultures (see below).

Another emerging technology for the identification of microorganisms is the use of PCR electrospray-ionization mass spectrometry (ESI/MS). This methodology uses conserved primers to generate PCR amplicons directly from a specimen source as well as MS to generate an approximation of the base content of the amplicons. This information is unique enough to develop spectral signatures for different organisms. These spectra are then compared to a database which provides likely identifications based on the primer sets used as well as the relative abundance of the organism(s) identified [30]. PCR ESI/MS has several advantages: (1) direct detection of a wide variety of potential pathogens (viruses, bacteria, and fungi) from specimens; (2) more rapid and cost-effective testing compared to sequencing technologies such as next-generation sequencing; and (3) to provide information outside the constraints of array-based technologies such as only being able to query a limited number of predefined organisms [30]. In fact, this technology can be used in pathogen discovery as new pathogens will not be identified but will group with similar known organisms. This was done successfully during the Sudden Acute Respiratory Syndrome (SARS) pandemic [31]. Still, as with all new technologies, work remains to be done to optimize the process for routine clinical use including further optimization of extraction methods as well as the development of additional primer sets.

Antimicrobial Resistance Detection

The increased emphasis on faster turnaround times for results combined with availability of more targeted therapeutics has created a niche for rapid molecular detection of resistance determinants in clinical microbiology laboratories. Antimicrobial resistance can be detected by probe hybridization, nucleic acid amplification (NAA) technologies such as PCR, and sequencing. However, the use of molecular methods to detect microbial resistance is not without its limitations. Multifactorial resistance mechanisms, polyclonal or polymicrobial infections, phenotypic synergism, and unknown genotype–phenotype relationships can prevent accurate determination of resistance using molecular methods.

Amplification Methods

Methicillin-Resistant Staphylococcus aureus

The most established application of molecular bacterial resistance testing is the detection of methicillin-resistant Staphylococcus aureus (MRSA). Resistance to methicillin in staphylococci is almost exclusively caused by a single mechanism, the alteration of the penicillin binding protein PBP2 to the conformer PBP2a. This change is mediated by a well-defined genetic component, the mecA gene. The altered PBP2a has a lower affinity for methicillin and other penicillinase-stable β-lactams such that resistance is conferred.
Traditional detection methods include chromogenic agars, oxacillin screening agars, and traditional disk diffusion for cefoxitin and minimum inhibitory concentration testing for oxacillin. These methods require 12–24 h of incubation. Decreasing the time to differentiate methicillin-susceptible staphylococcus aureus (MSSA) and MRSA by use of either protein-based methods (PB2a latex; Oxoid, Cambridge, UK) or molecular methods for the detection of the mecA gene (see below) is associated with improved patient outcomes and institutional cost savings [9, 32].

**Vancomycin-Resistant Enterococcus**

First detected nearly 30 years after the introduction of vancomycin, vancomycin-resistant enterococci (VRE) developed in part due to increasing use of vancomycin for *Clostridium difficile* colitis and MRSA infections [33, 34]. Vancomycin acts by blocking the transglycosylation and transpeptidation steps of cell wall biosynthesis. The resistance phenotype is based on lowering the affinity of vancomycin for its target peptidoglycan precursors and is encoded by the van genes. High-level resistance (MIC, ≥64 µg/ml) is encoded *vanA* and *vanB* which are typically found on transposons, or the chromosomally associated *vanD*, and is generally found in *Enterococcus faecium* and *Enterococcus faecalis* [35–37]. Also chromosomally encoded are the *vanC* genes of *Enterococcus gallinarum*, *Enterococcus casseliflavus*, and *Enterococcus flavescentis*, which are associated with low-level resistance (MIC, 2–32 µg/ml). Because *vanA* and *vanB* tend to reside on mobile elements and confer high-level resistance, detection of enterococci containing these resistance determinants is critical for effective infection control measures.

Although numerous laboratory-developed NAA assays and commercial analyte specific reagents (ASRs) are available, only a few assays for the molecular detection of VRE from rectal sites are cleared by the US Food and Drug Administration (FDA) (Xpert *vanA* test, Cepheid, Sunnyvale, CA; BD GeneOhm VanR, Becton Dickinson, Sparks, MD; and IMDX VanR, Intelligent Medical Devices, Beverly, MA). Although VRE in the USA and Europe most commonly contains *vanA*, *vanB* should also be considered due to its lower but significant prevalence. The main advantages to the molecular detection of VRE are increased sensitivity, increased specificity (exclusion of *vanC* mediated resistance), and decreased time-to-result [38–40].

**Mycobacterium tuberculosis**

Although resistance to antituberculosis drugs is not a new phenomenon, new methods have been developed to identify resistant strains. Due to the slow growth of *M. tuberculosis* (TB), molecular techniques are well suited to not only detect TB directly from patient specimens but also screen for resistance (see Chap. 53). Several test kits have been CE-marked for clinical use in Europe. These include the Genotype MTBDR system (Hain Lifescience, Germany), the Innogenetics INNO-LiPA Rif.TB (Gent, Belgium), and the Xpert MTB/RIF cartridge for the Cepheid GeneXpert platform, with the latter also receiving FDA clearance. All the systems detect rifampin resistance as it is the most common resistance found among the first-line TB drugs. In addition, rifampin resistance can be a marker for multidrug-resistant (MDR) TB in geographic regions with endemic MDR-TB [41]. Rifampin resistance is determined by analyzing the *rpoB* gene for specific mutations in the 81 bp rifampin resistance determining region using hybridization probes [42]. The Genotype MTBDR system also determines isoniazid resistance by screening the *katG* and *inhA* genes [43, 44]. An expanded Genotype MTBDRsl panel adds detection of resistance to fluoroquinolones, aminoglycosides, and ethambutol. Additional information on mycobacterial detection and resistance can be found in Chap. 53.

**Mass Spectrometry**

Much like the revolutionary impact on bacterial identifications, MS will likely impact resistance testing. Preliminary studies have demonstrated the rapid identification of MRSA, extended spectrum beta lactamase (ESBL) organisms, and carbapenemase-producing organisms by MALDI-TOF MS. Resistant organisms can be identified in two ways using MS. Similar to genetic approaches, resistant organisms can be identified by the presence or absence of characteristic mass peaks. This approach has been most widely used in the identification of MRSA by MS, though there are conflicting reports as to its effectiveness [45–47]. The other approach to identifying resistant organisms using MS is to apply a phenotypic approach such as measurement of substrate modification. For example, to determine the presence of a microbial carbapenemase, a carbapenem and test organism can be co-incubated followed by MS detection of native carbapenem drug peaks and/or peaks of its hydrolyzed products in the supernatant [48, 49]. Although this approach only detects resistance mechanisms that modify the substrate, it has the distinct advantage of looking for a phenotype instead of a particular resistance determinant. This can be especially useful in the cases of ESBLs and carbapenemases which have many genetic determinants that cause the same phenotype [50].

**Specific Applications**

**Staphylococcus aureus/MRSA**

Screening patients for MRSA nasal colonization is a central strategy for preventing the spread of this organism in healthcare settings. The reference method used to accurately detect
resistance due to altered PBP2 in *S. aureus* is NAA and detection of the *meca* gene. Conventional and real-time PCR have been used to detect *meca* both on bacterial isolates and directly on patient specimens. However, direct specimen testing has limitations, often including a lower positive predictive value than conventional methods based on the possible co-detection of MSSA and methicillin-resistant coagulase-negative staphylococci [51, 52]. Manufacturers have circumvented this problem through the detection of the SCCmec-orf junction in the *S. aureus* genome. However, strains that contain the SCCmec cassette but have a non-functional or deleted *meca* (so-called “meca-dropouts”) will be falsely positive. In addition, MRSA strains that carry mecC, a *meca* homologue, will be falsely negative in these assays, though the prevalence of these strains is still low [53]. Several FDA-cleared molecular assays are available for the detection of MRSA with or without MSSA detection from nasal swabs and clinical specimens, such as positive blood cultures and swabs obtained from skin and soft tissue infections (Table 49.1). NAA detection of MRSA is at least equal in sensitivity to culture-based methods, but has the advantage of offering a faster turnaround time, which, when combined with appropriate infection control interventions, may significantly decrease hospital costs by decreasing the number of health-care-associated MRSA infections [54].

**Group B Streptococcus (S. agalactiae)**

Although the incidence of Group B *Streptococcus* (GBS) neonatal disease has been declining since the 1990s due to enhanced prevention efforts, it is still the leading infectious cause of morbidity and mortality in neonates in the USA. In 2002, the Centers for Disease Control and Prevention (CDC), with the American College of Obstetricians and Gynecologists and the American Academy of Pediatrics, first published guidelines to perform vaginal–rectal screening of all pregnant women at 35–37 weeks gestation. Women who are colonized should be given intrapartum prophylactic treatment. Thus, accurate GBS results are critical to ensure appropriate antibiotic administration. Additionally, if a woman’s GBS colonization status is not known due to lack of prenatal care or premature delivery, she should receive prophylactic antibiotics based on risk assessment, specifically for gestation less than 37 weeks, membrane rupture more than 18 h prior to delivery, or a fever of greater than 38 °C [55]. Since antibiopic administration is not without risks to the mother and newborn, intrapartum rapid molecular tests for GBS colonization are beneficial.

The first molecular technique used for routine GBS screening was direct probe hybridization either to colonies or swab-inoculated Lim broth. Although this provided the advantage of decreased turnaround time and reduced technologist time [56], it is not cost-effective for routine antepartum screening. Further development of molecular technologies in GBS detection has resulted in seven FDA-cleared molecular tests (Table 49.2) and numerous laboratory-developed tests (LDTs). Notably, the BD GeneOhm StreptB test (BD GeneOhm Sciences, San Diego, CA) and the Cepheid Smart GBS and Xpert GBS offer detection of GBS directly from rectovaginal swabs for antepartum or intrapartum detection of GBS colonization. FDA-cleared in 2006, Xpert GBS performed on the GeneXpert (Cepheid) is a moderate-complexity test that is self-contained from extraction to result. This technology makes random access testing for intrapartum screening feasible. Given that approximately 10 % of women with negative cultures at 35–37 weeks’ gestation are GBS positive at the time of delivery [57],

| Test name                        | Manufacturer       | Organism(s) detected | Specimen types       | References |
|----------------------------------|--------------------|----------------------|----------------------|------------|
| **Screening tests**              |                    |                      |                      |            |
| GeneOhm MRSA ACP                 | BD Diagnostics     | MRSA                 | Nasal swab           | [77]       |
| IDI-MRSA                         | BD Diagnostics     | MRSA                 | Nasal swab           | [78–81]    |
| LightCycler MRSA Advanced        | Roche Molecular Diagnostics | MRSA | Nasal swab           | [82]       |
| NucliSens EasyQ MRSA             | bioMérieux         | MRSA                 | Nasal swab           | –          |
| Xpert MRSA                       | Cepheid            | MRSA                 | Nasal swab           | [79, 83]   |
| Xpert SA Nasal Complete          | Cepheid            | MRSA/SA              | Nasal swab           | [84]       |
| **Diagnostic tests**             |                    |                      |                      |            |
| GeneOhm StaphSR                  | BD Diagnostics     | MRSA                 | Positive blood cultures | [85, 86] |
| Filmarray BCID                   | BioFire            | MRSA/SA              | Positive blood culture bottles | [101]    |
| Verigene BC-GP Nucleic Acid      | Nanosphere         | MRSA/SA              | Positive blood cultures | [87–89]   |
| Xpert MRSA/SA BC                 | Cepheid            | MRSA/SA              | Positive blood cultures | [90–92]   |
| Xpert MRSA/SA SSTI               | Cepheid            | MRSA/SA              | Skin/soft tissue swabs | [92, 93]   |
intrapartum testing is the most accurate test for colonization at the time of delivery. As an intrapartum screening test at one institution, the Xpert GBS had a sensitivity of 95.8 % and specificity of 64.5 %, whereas the antenatal culture was 83.3 % sensitive and 80.6 % specific, when intrapartum culture was used as the gold standard [58]. In a multicenter study of the IDI-StrepB assay (BD GeneOhm), when intrapartum culture was the gold standard, molecular detection at the time of labor was 94 % sensitive and 95.9 % specific [59]. Relative to either the sensitivity of antenatal cultures (54 %) or risk factor analysis (42 %), the sensitivity of the IDI-StrepB assay was superior [59]. The advantage in all these applications is the decreased turnaround time relative to culture in the intrapartum setting. Additional data regarding the sensitivity and specificity of molecular tests for GBS detection is shown in Table 49.2.

### Table 49.2 FDA-cleared molecular tests for detection of group B *Streptococcus*

| Test name         | Manufacturer         | Methodology                                      | Specimen tested                  | Sensitivity* | Specificity* | References |
|-------------------|----------------------|--------------------------------------------------|-----------------------------------|--------------|--------------|------------|
| BD Max GBS        | BD GeneOhm           | Real-time PCR                                    | Enrichment broth, antepartum swabs| 95 %*        | 96.7 %*      | [94]       |
| Strep B (IDI-Strep B) | BD GeneOhm           | Real-time PCR                                    | Direct swab, antepartum and intrapartum | 94 %*        | 96 %*        | [59, 95–97] |
| Smart GBS         | Cepheid              | Real-time PCR                                    | Direct swab, antepartum and intrapartum | 81.6–98.7 %* | 90.4–96.3 %* | [98, 99]   |
| Xpert GBS         | Cepheid              | Real-time PCR                                    | Direct swab, antepartum and intrapartum | 88.6 %*      | 96.7 %*      | [58, 100]  |
| Illumigene GBS    | Meridian Bioscience  | Loop-mediated isothermal amplification           | Enrichment broth of antepartum swabs| 97.4 %*      | 92.3 %*      | [102]      |
| Group B AccuProbe | Gen-Probe            | Hybridization Protection Assay                   | Enrichment broth or cultured isolate| 97.7 %*      | 99.1 %*      | [56, 97, 101] |
| GBS PNA FISH      | AdvanDx              | Fluorescent in situ hybridization                 | Enrichment broth of antepartum swabs | 89.2 %*      | 98.1 %*      | [99]       |

*Sensitivities and specificities were calculated using culture as the gold standard and vary depending on whether used for antepartum or intrapartum screening in the cited reference. Package insert data are indicated by an asterisk (*)

The use of molecular methods for the diagnosis of sepsis has been a challenging endeavor. Only one FDA-approved test is available for the identification of potential pathogens directly from blood obtained from septic patients, and this test is limited to candidemia. The gold standard remains automated blood cultures, and this reference method may be difficult to match owing to the large amount of blood that is cultured (typically 40 ml). Nonetheless, research use only products are available for direct testing of blood. Roche Molecular Systems SeptiFast (Branchburg, NJ) uses multiplex real-time PCR and melt curve analysis, while the Molzym SepsiTTest (Bremen, Germany) uses multiplex PCR followed by sequencing, and the SIRS-Lab Vyoo (Jena, Germany) uses multiplex PCR followed by gel electrophoresis. These products vary in both the organisms and the resistance determinants detected, as well as analytical performance characteristics [60–64]. In general, these products suffer from both a lack of sensitivity and specificity, as well as requiring additional optimization before routine clinical use is possible.

Other shortcomings of NAA-based diagnosis of sepsis include the inconclusive clinical significance of the detection of pathogen DNA in the blood stream and the inability to obtain full antimicrobial susceptibility results [62]. However, blood culture is an imperfect reference method, suffering from a number of limitations including a prolonged time to pathogen identification, effects of variable blood volume, and lack of growth for fastidious pathogens or in the presence of prior antimicrobial therapy [62]. One limitation that can be addressed by molecular methods is the time to definitive identification.

A number of commercial molecular testing products are available for the identification of organisms and resistant determinants directly from positive blood culture bottles. This approach takes advantage of the culture amplification of bacteria from blood while adding molecular methods to lessen the time to identification. FDA-cleared tests for use directly with positive blood culture bottles include AdvanDx PNA-FISH (Woburn, MA), Cepheid (Sunnyvale, CA), Biofire FilmArray BC-ID (Salt Lake City, UT) and Nanosphere BC-GP and BC-GN panels (Northbrook, IL). The molecular targets for each of these products are listed in Table 49.3. The use of MALDI-TOF MS in direct pathogen detection directly from positive blood cultures also is being investigated [65, 66]. Recent data show identification rates of
approximately 85%, while reducing time to identification by more than a day [67]. Several studies have demonstrated the cost-effectiveness of utilizing rapid detection of organisms from positive blood culture bottles [8, 9, 11].

**Table 49.3** FDA-cleared molecular tests for identification of potential pathogens from positive blood culture bottles

| Test name     | Manufacturer | Methodology | Organisms detected | Resistance detected |
|---------------|--------------|-------------|--------------------|---------------------|
| AdvanDx       | Separate tests as listed in Organisms Detected column | PNA-FISH      | Candida albicans   | Not directly; inferred from some species identifications |
|               |              |             | C. albicans/glabrata   |                     |
|               |              |             | Yeast Traffic Light\(a\) |                     |
|               |              |             | Enterococcus faecalis/OE\(b\) |                     |
|               |              |             | E. coli/P. aeruginosa |                     |
|               |              |             | EK/P. aeruginosa   |                     |
|               |              |             | GNR Traffic Light\(a\) |                     |
| Becton Dickinson | StaphSR      | Real-time PCR | Staphylococcus aureus | mecA (MRSA) |
| Cepheid       | Xpert MRSA/SA BC | Real-time PCR | Staphylococcus aureus | mecA (MRSA) |
| Nanosphere    | Verigene BC-GP | Multiplex gold nanoparticle probes | Staphylococcus spp. | mecA (MRSA) |
|               |              |             | Streptococcus spp. | vanA (VRE) |
|               |              |             | Listeria spp. | vanB (VRE) |
|               |              |             | Staphylococcus aureus |                     |
|               |              |             | Staphylococcus epidermidis |                     |
|               |              |             | Staphylococcus lugdunensis |                     |
|               |              |             | Streptococcus pneumonia |                     |
|               |              |             | Streptococcus anginosus group |                     |
|               |              |             | Streptococcus agalactiae |                     |
|               |              |             | Streptococcus pyogenes |                     |
|               |              |             | Enterococcus faecalis |                     |
|               |              |             | Enterococcus faecium |                     |
| Nanosphere    | Verigene BC-GN |                      | Escherichia coli |                     |
|               |              |             | Klebsiella pneumoniae |                     |
|               |              |             | Klebsiella oxytoca |                     |
|               |              |             | Pseudomonas aeruginosa |                     |
|               |              |             | Serratia marcescens |                     |
| BioFire       | Filmarray BCID |                      | Escherichia coli K1 |                     |
|               |              |             | Haemophilus influenzae |                     |
|               |              |             | Listeria monocytogenes |                     |
|               |              |             | Neisseria meningitidis |                     |
|               |              |             | Streptococcus agalactiae |                     |
|               |              |             | Streptococcus pneumoniae |                     |

\(a\)Candida albicans/parapsilosis, Candida tropicalis, Candida glabrata/krusei

\(b\)Other enterococci

\(c\)Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa

**Molecular Epidemiology**

Pulsed field gel electrophoresis (PFGE) is the gold standard for molecular epidemiology studies of the majority of organisms [68]. In brief, bacterial cells are immobilized in agarose and subjected to proteolytic degradation followed by restriction endonuclease digestion. The resulting genomic fragments are separated by PFGE which allows for better resolution of high molecular weight products [69]. PFGE is a critical tool for infection control and public health specialties, as a proven reproducible method to show strain relatedness and identify outbreaks. Other common approaches to molecular epidemiology include amplified fragment length polymorphism (AFLP) analysis and multi locus sequence typing (MLST) [70]. AFLP analysis is based on the same theory as PFGE: differences in DNA sequence can be identified by differences in restriction endonuclease patterns. The major difference between AFLP analysis and PFGE is that PFGE looks at the entire genome of an organism, while AFLP analysis emphasizes regions of the genome known to have high rates of polymorphisms. MLST analysis is done by amplifying and sequencing a small set of known housekeeping genes (usually 7–14) that have a standard rate of genetic variability.
These labor-intensive, and often expensive, approaches to molecular epidemiology have their disadvantages. Although PFGE has high discriminatory power, it is not very reproducible even amongst members of the same laboratory. This variability makes longitudinal comparisons difficult and often requires the same strains to be run repeatedly and/or implementation of a standard strain to normalize banding patterns. Although MLST analysis is very reproducible, it lacks the discriminatory power that more genome wide approaches such as AFLP analysis and PFGE offer. AFLP analysis tries to combine the discriminatory power of PFGE with the reproducibility of MLST analysis, with some success, but this approach is not applicable to all organisms [68].

MALDI-TOF MS represents a promising development for the field of molecular epidemiology, providing a relatively fast and easy method of comparing strain relatedness, with minimal hands-on time. MALDI-TOF MS has the advantage of interrogating the entire proteome of a microorganism, although the protein size range analyzed is typically only 2–20 kDa. Researchers have looked at the ability of MALDI-TOF MS to distinguish bacterial subspecies of organisms such as Salmonella [71, 72]. Only a few studies have been performed that compare the ability of a MALDI-TOF MS system directly to PFGE and assess its ability to determine absolute strain relatedness [73]. MALDI-TOF MS has been used to identify clonal populations of MRSA with some success [74], but the accuracy of this has been debated [75]. It remains to be seen, however, if the level of resolution of MALDI-TOF MS fingerprinting is enough to allow this technology to replace PFGE in the epidemiologic investigations of microorganisms.

**Future Perspectives**

Advances in molecular biology in the last 10–15 years have made an astounding impact on clinical laboratory testing for infectious diseases. Notably, TB can be confirmed in 24 h as opposed to 6–8 weeks, sexually transmitted infections such as those caused by C. trachomatis and N. gonorrhoeae can be rapidly and accurately identified improving treatment and prevention of transmission, and organisms with important infection control implications such as B. pertussis, MRSA, and VRE, can be quickly identified leading to appropriate therapy and/or precautions. The applications of molecular technology in clinical microbiology are endless, but disadvantages also abound. A molecular infectious disease laboratory is established only with considerable cost and expertise. Further, we are still learning what many NAA test results mean in terms of infectious etiology and clinical significance [76]. Is the mere presence of a microorganism’s DNA convincing evidence of disease causation? Additional clinical and scientific evidence may be needed to validate the clinical relevance molecular-based results.

Though there is still much to be learned about the appropriate application and interpretation of molecular infectious disease testing, numerous exciting opportunities are on the horizon. The use of real-time PCR testing in the clinical laboratory has revolutionized diagnostic microbiology. The expanding capacity of multiplex technologies is allowing the simultaneous detection of over 20 analytes in just over an hour (BioFire Diagnostics). Perhaps the technology with the greatest impact on clinical microbiology is the use of MALDI-TOF MS not only for the identification of organisms, but also their potential resistance profiles and strain typing. Lastly, as next-generation sequencing becomes more affordable and accessible to clinical laboratories, clinical investigators will be able to ask questions about pathogenesis and microbiome changes in real time. Never before has clinical microbiology changed at the rapid pace we are currently experiencing. We must remember that the power of molecular technologies should be coupled with well-controlled and clinically relevant diagnostic approaches to have the greatest impact on patient care.

**References**

1. Tenover FC. DNA hybridization techniques and their application to the diagnosis of infectious diseases. Infect Dis Clin North Am. 1993;7(2):171–81.
2. Lebrun L, Espinasse F, Poveda JD, Vincent-Levy-Frebault V. Evaluation of nonradioactive DNA probes for identification of mycobacteria. J Clin Microbiol. 1992;30(9):2476–8.
3. Lumb R, Lancers JA, Lim IS. Rapid identification of mycobacteria by the Gen-Probe Accuprobe system. Pathology. 1993;25(3):313–5.
4. Butler WR, O’Connor SP, Yakrus MA, Gross WM. Cross-reactivity of genetic probe for detection of Mycobacterium tuberculosis with newly described species Mycobacterium celatum. J Clin Microbiol. 1994;32(2):536–8.
5. Ford EG, Sneed SJ, Todd J, Warren NG. Strains of Mycobacterium terrae complex which react with DNA probes for M. tuberculosis complex. J Clin Microbiol. 1993;31(10):2805–6.
6. Moter A, Gobel UB. Fluorescence in situ hybridization (FISH) for direct visualization of microorganisms. J Microbiol Methods. 2000;41(2):85–112.
7. Perry-O’Keefe H, Rigby S, Oliveira K, Sorensen D, Stender H, Coull J, Hyldig-Nielsen JJ. Identification of indicator microorganisms using a standardized PNA FISH method. J Microbiol Methods. 2001;47(3):281–92.
8. Forrest GN, Mankes K, Jabra-Rizk MA, Weekes E, Johnson JK, Lincalis DP, Venezia RA. Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs. J Clin Microbiol. 2006;44(9):3381–3.
9. Forrest GN, Mehta S, Weekes E, Lincalis DP, Johnson JK, Venezia RA. Impact of rapid in situ hybridization testing on coagulase-negative staphylococci positive blood cultures. J Antimicrob Chemother. 2006;58(1):154–8.
10. Heil EL, Daniels LM, Long DM, Rodino KG, Weber DJ, Miller MB. Impact of a rapid peptide nucleic acid fluorescence in situ hybridization assay on treatment of Candida infections. Am J Health Syst Pharm. 2012;69(21):1910–4.
11. Ly T, Gulia J, Pyrgos V, Wag M, Shoham S. Impact upon clinical outcomes of translation of PNA FISH-generated laboratory data from the clinical microbiology bench to bedside in real time. Ther Clin Risk Manag. 2008;4(3):637–40.

12. Fournier PE, Thuny F, Richet H, Lepidi H, Casalta JP, Arzouni JP, Maurin M, Celard M, Mainardi JL, Caus T, Collart F, Habib G, Raoult D. Comprehensive diagnostic strategy for blood culture-negative endocarditis: a prospective study of 819 new cases. Clin Infect Dis. 2010;51(2):131–40.

13. Miyazato A, Ohkus K, Tabata M, Uwabe K, Kawamura T, Tachi Y, Ezaki T, Niinami H, Mitsutake K. Comparative molecular and microbiological diagnosis of 19 infective endocarditis cases in which causative microbes were identified by PCR-based DNA sequencing from the excised heart valves. J Infect Chemother. 2012;18(3):318–23.

14. Claridge III JE. Impact of 16S rRNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious diseases. Clin Microbiol Rev. 2004;17(4):840–62.

15. Convilie PS, Zelazny AM, Witebsky FG. Analysis of secA1 gene sequences for identification of Nocardioid species. J Clin Microbiol. 2006;44(8):2760–6.

16. Roth A, Fischer M, Hamid ME, Michalke S, Ludwig W, Mauch H. Differentiation of phylogenetically related slowly growing mycobacteria based on 16S–23S rRNA gene internal transcribed spacer sequences. J Clin Microbiol. 1998;36(1):139–47.

17. Zelazny AM, Root JM, Shea YR, Colombo RE, Shamputa IC, Stock F, Conlan S, McNulty S, Brown-Elliott BA, Wallace Jr RJ, Olivier KN, Holland SM, Sampaio EP. Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii. J Clin Microbiol. 2009;47(7):1985–95.

18. Patel R. Matrix-assisted laser desorption ionization-time of flight mass spectrometry in clinical microbiology. Clin Infect Dis. 2013;57(4):564–72.

19. Anhalt JP, Fenselau C. Identification of bacteria using mass spectrometry. Anal Chem. 1975;47(2):219–25.

20. Cain TC, Lubman DM, Weber WJ, Vertes A. Differentiation of bacteria using protein profiles from matrix-assisted laser desorption/ionization/time-of-flight mass spectrometry. Rapid Commun Mass Spectrom. 1994;8(12):1026–30.

21. Holland RD, Wilkes JG, Rafi S. Differentiation of phylogenetically related slowly growing mycobacteria based on 16S-23S rRNA gene internal transcribed spacer sequences. J Clin Microbiol. 1998;36(1):139–47.

22. Claydon MA, Davey SN, Edwards-Jones V, Gordon DB. The rapid identification of intact microorganisms using mass spectrometry. Nat Biotechnol. 1996;14(11):1584–8.

23. Couturier MR, Melinovic E, Croft AC, Fisher MA. Identification of HACEK clinical isolates by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2011;49(3):1104–6.

24. Fedorko DP, Drake SK, Stock F, Murray PR. Identification of clinical isolates of anaerobic bacteria using matrix-assisted laser desorption ionization-time of flight mass spectrometry. Eur J Clin Microbiol Infect Dis. 2012;31(9):2257–62.

25. Wybo I, Soetens O, De Bel A, Echahidi F, Vancutsem E, Vandoorslaer Y, Pierson C, Tack K, Pierard D. Species identification of clinical Prevotella isolates by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2012;50(4):1415–8.

26. Chen JH, Yan WC, Ngn AH, Fung AM, Woo WL, Yan MK, Choi GK, Ho PL, Cheng VC, Yuen KY. Advantages of using matrix-assisted laser desorption ionization-time of flight mass spectrometry as a rapid diagnostic tool for identification of yeasts and mycobacteria in the clinical microbiological laboratory. J Clin Microbiol. 2013;51(12):3981–7.

27. Saleeb PG, Drake SK, Murray PR, Zelazny AM. Identification of mycobacteria in solid-culture media by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2011;49(5):1790–4.

28. Cherkauoi A, Hibbs J, Emonet S, Tangomo M, Girard P, Schrenzel J. Comparison of two matrix-assisted laser desorption ionization-time of flight mass spectrometry methods with conventional phenotypic identification for routine identification of bacteria to the species level. J Clin Microbiol. 2010;48(4):1169–75.

29. Martiny D, Busson L, Wybo I, El Haj RA, Dediste A, Vandenberg O. Comparison of the Microflex LT and Vitek MS systems for routine identification of bacteria by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2012;50(4):1313–25.

30. Ecker DJ, Sampath R, Massire C, Blyn LB, Hall TA, Eshoo MW, Hofstadler SA. Ibis T5000: a universal biosensor approach for microbiology. Nat Rev Microbiol. 2008;6(7):553–8.

31. Sampath R, Hofstadler SA, Blyn LB, Eshoo MW, Hall TA, Massire C, Levene HM, Hanss JC, Harrell PM, Neuman B, Buchmeier MJ, Jiang Y, Ranken R, Drader JJ, Samant V, Griffey RH, McNeil JA, Crooke ST, Ecker DJ. Rapid identification of emerging pathogens: coronavirus. Emerg Infect Dis. 2005;11(3):373–9.

32. Andersen BM, Tollefsen T, Seljordslia B, Hochlin K, Syversen G, Jonassen TO, Rasch M, Sandvik L. Rapid MRSA test in exposed persons: costs and savings in hospitals. J Infect. 2010;60(4):293–9.

33. Aubry-Damon H, Soussy CJ, Courvalin P. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 1998;42(10):2590–4.

34. Luben AD, Jacobs RA, Jordan M, Guglielmo BJ. Relative importance of oral versus intravenous vancomycin exposure in the development of vancomycin-resistant enterococci. J Infect Dis. 1996;173(5):1292–4.

35. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev. 2000;13(4):686–707.

36. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis. 2006;42 Suppl 1:S25–34.

37. Depardieu F, Reynolds PE, Courvalin P. VanD-type vancomycin-resistant Enterococcus faecium 10/96A. Antimicrob Agents Chemother. 2003;47(1):7–18.

38. Espy MJ, Uh1 JR, Sloan LM, Buckwalter SP, Jones MF, Vetter EA, Yao JD, Wengenack NL, Rosenblatt JE, Cockerill FR III, Smith TF. Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clin Microbiol Rev. 2006;19(1):165–256.

39. Zirakzadeh A, Patel R. Epidemiology and mechanisms of glycopeptide resistance in enterococci. Curr Opin Infect Dis. 2005;18(6):507–12.

40. Sloan LM, Uh1 JR, Vetter EA, Schleck CD, Hamsen WS, Manahan J, Thompson RL, Rosenblatt JE, Cockerill FR III. Comparison of the Roche LightCycler van/Alvani detection assay and culture for detection of vancomycin-resistant enterococci from perianal swabs. J Clin Microbiol. 2004;42(6):2636–43.

41. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Skrifvars MB, Snajdovski K, Grassal C, Strickert J, Enderle H, Weinert B, Kroll S, Ruhland M, Seifert H, Wirth J, Klumper K, Kramer A, Kahlert M, Schmidt S, Link A, Testa M, Kallmeyer D, Weihmann C, Teuscher U, Antal C, Urbach J, Taubenberger M, Schuren C, Rose D, Riess P, Grunert D, Tatzber F, Haidl S, Schubauer-Booth A, von Winterfeldt D, Dierking K, Zhang D, Goto T, Kajitani S, Hattori M, Hasegawa Y, Fujimura A, Usuda D, Shimizu T, Umemura M, Sakurai H, Ono H, Kato M, Seki A, Kato K, Kubo K, Ando Y, Nakamura K, Kamata T, Fujisawa K, Sato T, Ishihama Y, Kubo H. Use of a TaqMan-based nuclease-particle array assay for rapid detection of mycobacteria. J Clin Microbiol. 2006;44(7):2333–7.
44. Lavender C, Globan M, Sievers A, Billman-Jacobe H, Fyfe J. Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis isolates collected in Australia. Antimicrob Agents Chemother. 2005;49(10):4068–74.

45. Bernardo K, Pakulat N, Macht M, Krut O, Seifert H, Fleer S, Hunger F, Kronke M. Identification and discrimination of Staphylococcus aureus strains using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Proteomics. 2002;2(6):747–53.

46. Du Z, Yang R, Guo Z, Song Y, Wang J. Identification of *Staphylococcus aureus* and determination of its methicillin resistance by matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Anal Chem. 2002;74(21):5487–91.

47. Edwards-Jones V, Clayton MA, Evasion DJ, Walker J, Fox AJ, Gordon DB. Rapid discrimination between methicillin-sensitive and methicillin-resistant *Staphylococcus aureus* by intact cell mass spectrometry. J Med Microbiol. 2000;49(3):295–300.

48. Burckhardt I, Zimmermann S. Using matrix-assisted laser desorption ionization-time of flight mass spectrometry to detect carbapenem resistance within 1 to 2.5 hours. J Clin Microbiol. 2011;49(9):3321–4.

49. Hrabak J, Walkova R, Studentova V, Chudackova E, Bergerova T. Carbapenemase activity detection by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2011;49(9):3222–7.

50. Sparbier K, Schubert S, Weller U, Boogen C, Kostrzewa M. Matrix-assisted laser desorption ionization-time of flight mass spectrometry-based functional assay for rapid detection of resistance against beta-lactam antibiotics. J Clin Microbiol. 2012;50(3):927–37.

51. Becker K, Pagnier I, Schuhen B, Wenzelburger F, Friedrich AW, Kipp F, Peters G, von Eiff C. Does nasal coculonization by methicillin-resistant coagulase-negative staphylococci and methicillin-susceptible *Staphylococcus aureus* strains occur frequently enough to represent a risk of false-positive methicillin-resistant *S. aureus* determinations by molecular methods? J Clin Microbiol. 2006;44(1):229–31.

52. Desjardins M, Guibord C, Lanolde B, Toye B, Ramotar K. Evaluation of the IDI-MRSA assay for detection of methicillin-resistant *Staphylococcus aureus* from nasal and rectal specimens pooled in a selective broth. J Clin Microbiol. 2006;44(4):1219–23.

53. Paterson GK, Harrison EM, Holmes MA. The emergence of mecC methicillin-resistant *Staphylococcus aureus*. Trends Microbiol. 2014;22(1):42–7.

54. Robicsek A, Beaumant JL, Paule SM, et al. Universal surveillance for methicillin-resistant *Staphylococcus aureus* in 3 affiliated hospitals. Ann Int Med. 2008;148(6):409–18.

55. Centers for Disease Control and Prevention. Prevention of perinatal group B *Streptococcus* colonization. J Clin Microbiol. 1997;35(1):144–7.

55. Centers for Disease Control and Prevention. Quick reference guide for Identification and reporting of group B streptococcal isolates. J Clin Microbiol. 2005;43(1):394–404.

56. Asrat T, Rumney P, Towers C, Preslicka C. The accuracy of late third trimester antenatal screening for group B *Streptococcus* in predicting GBS colonization at delivery. Am J Obstet Gynecol. 2006;195(6):S40.

57. Davies HD, Miller MA, Faro S, Gregson D, Kehl SC, Jordan JA. Multicenter study of a rapid molecular-based assay for the diagnosis of group B *Streptococcus* colonization in pregnant women. Clin Infect Dis. 2004;39(8):1129–35.

58. Fitting C, Parlato M, Adib-Conquy M, Memain N, Philippart F, Missset B, Monchi M, Cavaillon JM, Adrie C. DNAemia detection by multiplex PCR and biomarkers for infection in systemic inflammatory response syndrome patients. PLoS One. 2012;7(6):e38916.

59. Josefson P, Stralin K, Ohlin A, Ennefors T, Dragsten B, Andersson L, Fredlund H, Molling P, Olen P. Evaluation of a commercial multiplex PCR test (SeptiFast) in the etiological diagnosis of community-onset bloodstream infections. Eur J Clin Microbiol Infect Dis. 2011;30(9):1127–34.

60. Mancini N, Carletti S, Ghidoli N, Cichero P, Burioni R, Clementi M. The era of molecular and other non-culture-based methods in diagnosis of sepsis. Clin Microbiol Rev. 2010;23(1):235–51.

61. Pasqualini L, Mencacci A, Leli C, Montagna P, Cardaccia A, Cenci E, Montecarlo I, Pirro M, di Filippo F, Cistaro E, Schillaci G, Bistoni F, Mannarino E. Diagnostic performance of a multiple real-time PCR assay in patients with suspected sepsis hospitalized in an internal medicine ward. J Clin Microbiol. 2012;50(4):1285–8.

62. Wellingshausen N, Kochm AJ, Disque C, Muhl H, Gebert S, Winter J, Matten J, Sakka SG. Diagnosis of bacteremia in whole-blood samples by use of a commercial universal 16S rRNA gene-based PCR and sequence analysis. J Clin Microbiol. 2009;47(9):2759–65.

63. Martinez RM, Bauerle ER, Fang FC, Butler-Wu SM. Evaluation of three rapid diagnostic methods to directly identify microorganisms from positive blood cultures. J Clin Microbiol. 2014;52(7):2521–9.

64. Jamal W, Saleem R, Rotimi VO. Rapid identification of pathogens directly from blood culture bottles by Bruker matrix-assisted laser desorption ionization-time of flight mass spectrometry versus routine methods. Diagn Microbiol Infect Dis. 2013;76(4):404–8.

65. Buchan BW, Riebe KM, Ledeboer NA. Comparison of the MALDI Biotyper system using Sepsityper specimen processing to routine microbiological methods for identification of bacteria from positive blood culture bottles. J Clin Microbiol. 2012;50(2):346–52.

66. Westbrook G, Holmes H. Epidemiologic strain typing. In: Garcia LS, editor. Clinical microbiology procedures handbook. 3rd ed. Washington, DC: ASM Press; 2010. p. 1–6.

67. Schwartz DC, Cantor CR. Separation of yeast chromosome-sized DNAs by pulsed field gradient gel electrophoresis. Cell. 1984;37(1):67–75.

68. Li W, Raoult D, Fournier PE. Bacterial strain typing in the genomic era. FEMS Microbiol Rev. 2009;33(5):892–916.

69. Dieckmann R, Malorny B. Rapid screening of epidemiologically important *Salmonella enterica* subsp. enterica serovars by whole-cell matrix-assisted laser desorption ionization-time of flight mass spectrometry. Appl Environ Microbiol. 2011;77(12):4136–46.

70. Kuhns M, Zautner AE, Rabsch W, Zimmermann O, Weig M, Bader O, Gross U. Rapid discrimination of *Salmonella enterica* serovar typhi from other serovars by MALDI-TOF mass spectrometry. PLoS One. 2012;7(6):e40004.

71. Fujinami Y, Kikikawa HS, Kurosaki Y, Sakurada K, Yoshino M, Yasuda J. Rapid discrimination of *Legionella* by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Microbiol Res. 2011;166(2):77–86.

72. Wolters M, Rohde H, Maier T, Belmar-Campos C, Franke G, Scherpe S, Aepfelbacher M, Christner M. MALDI-TOF MS fingerprinting allows for discrimination of major methicillin-resistant *Staphylococcus aureus* lineages. Int J Med Microbiol. 2011;301(1):64–8.

73. Lasch P, Fleige C, Stammmeier L, Yasser U, Witte W, Werner G. Insufficient discriminatory power of MALDI-TOF mass spec-
tometry for typing of *Enterococcus faecium* and *Staphylococcus aureus* isolates. J Microbiol Methods. 2014;100:58–69.

76. Fredericks DN, Relman DA. Sequence-based identification of microbial pathogens: a reconsideration of Koch’s postulates. Clin Microbiol Rev. 1996;9(1):18–33.

77. Patel PA, Ledeboer NA, Ginocchio CC, Condon S, Bouchard S, Qin P, Karchmer T, Peterson LR. Performance of the BD GeneOhm MRSA achromopeptidase assay for real-time PCR detection of methicillin-resistant *Staphylococcus aureus* in nasal specimens. J Clin Microbiol. 2011;49(6):2265–8.

78. Bischof LJ, Lapsley L, Fontecchio K, Jacobsen D, Young S, Halkerst JD, Newton DW. Comparison of chromogenic media to BD GeneOhm methicillin-resistant *Staphylococcus aureus* (MRSA) PCR for detection of MRSA in nasal swabs. J Clin Microbiol. 2009;47(7):2281–3.

79. Hombach M, Pfyffer GE, Roos M, Lucke K. Detection of methicillin-resistant *Staphylococcus aureus* (MRSA) in specimens from various body sites: performance characteristics of the BD GeneOhm MRSA assay, the Xpert MRSA assay, and broth-enriched culture in an area with a low prevalence of MRSA infections. J Clin Microbiol. 2010;48(11):3882–7.

80. Paule SM, Mehta M, Hacek DM, González TM, Robicsek A, Peterson LR. Chromogenic media vs. real-time PCR for nasal surveillance of methicillin-resistant *Staphylococcus aureus*: impact on detection of MRSA-positive persons. Am J Clin Pathol. 2009;131(4):532–9.

81. Snyder JW, Munier GK, Johnson CL. Comparison of the BD GeneOhm methicillin-resistant *Staphylococcus aureus* (MRSA) PCR assay to culture by use of BBL CHROMagar MRSA for detection of MRSA in nasal surveillance cultures from intensive care unit patients. J Clin Microbiol. 2010;48(4):1305–9.

82. Peterson LR, Liesenfeld O, Woods CW, Allen SD, Pombo D, Patel PA, Mehta MS, Nicholson B, Fuller D, Onderdonk A. Multicenter evaluation of the LightCycler methicillin-resistant *Staphylococcus aureus* (MRSA) advanced test as a rapid method for detection of MRSA in nasal surveillance swabs. J Clin Microbiol. 2010;48(5):1661–6.

83. Wolk DM, Picton E, Johnson D, Davis T, Pancholi P, Ginocchio CC, Finegold S, Welch DF, de Boer M, Fuller D, Solomon MC, Rogers B, Mehta MS, Peterson LR. Multicenter evaluation of the Cepheid Xpert methicillin-resistant *Staphylococcus aureus* (MRSA) test as a rapid screening method for detection of MRSA in nares. J Clin Microbiol. 2009;47(3):758–64.

84. Patel PA, Schora DM, Peterson KE, Grayes A, Boehm S, Peterson LR. Performance of the Cepheid Xpert(R) SA Nasal Complete PCR assay compared to culture for detection of methicillin-sensitive and methicillin-resistant *Staphylococcus aureus* colonization. Diagn Microbiol Infect Dis. 2014;80(1):32–4.

85. Frey AB, Wilson DA, LaSalvia MM, Tan CD, Rodriguez ER, Shrestha NK, Hall GS, Procop GW. The detection and differentiation of methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* endocarditis by using the BD GeneOhm StaphSR Assay. Am J Clin Pathol. 2011;136(5):686–9.

86. Stamper PD, Cai M, Howard T, Speser S, Carroll KC. Clinical validation of the molecular BD GeneOhm StaphSR assay for direct detection of *Staphylococcus aureus* and methicillin-resistant *Staphylococcus aureus* in positive blood cultures. J Clin Microbiol. 2007;45(7):2191–6.

87. Buchan BW, Ginocchio CC, Manii R, Cavagnolo R, Pancholi P, Sweeney L, Thomson JR KB, Anderson C, Kaul K, Ledeboer NA. Multiplex identification of gram-positive bacteria and resistance determinants directly from positive blood culture broth: evaluation of an automated microarray-based nucleic acid test. PLoS Med. 2013;10(7):e1001478.